Total Live Articles: 427

Vestibular Schwannoma

EANO guideline on the diagnosis and treatment of vestibular schwannoma. Published: Oct 2019.

Vestibular Schwannoma

Vestibular schwannoma, formerly known as acoustic neuroma, is a benign intracranial tumour arising from cranial nerve VIII (vestibulocochlear nerve).

This updated UKMLA guide to vestibular schwannoma is based on EANO guideline, which covers causes, risk factors, symptoms, diagnosis, and management.

Relevant Anatomy

Vestibular schwannomas arise from the cranial nerve VIII (vestibulocochlear nerve)

  • ~80% arise from the vestibular portion
  • ~20% arise from the cochlear portion

Anatomical location:

  • The tumour is located inside the internal acoustic canal
  • As the tumour grows larger, it can protrude out of the internal acoustic canal, extending into the cerebellopontine angle (a fluid-filled space located at the junction of the cerebellum and the pons of the brainstem)

Vestibular schwannomas make up >80% of all tumours found in the cerebellopontine angle, making them the most common extra-axial posterior fossa tumours in adults

Epidemiology

Incidence increases with age (peak at 65-74 y/o)

Racial variations:

  • Highest among Caucasian population
  • Lowest among Black and Hispanic populations

Causes and Risk Factors

Vestibular schwannoma is primarily driven by genetic alterations (even in non-inherited cases):

  • NF2 tumour suppressor gene inactivation (seen in ~77% cases)
  • Neurofibromatosis type 2
    • Associated with 4-6% of vestibular schwannoma cases
    • Autosomal dominant monogenic condition that causes bilateral tumours (→ bilateral vestibular schwannoma)

Specific environmental or lifestyle risk factors for vestibular schwannoma are not well established

  • Risk is higher in parous women (compared to nulliparous)
  • Risk is lower in current smokers (but not ex-smokers)

Clinical Features

Typically presents as unilateral:

  • Progressive sensorineural hearing loss (most common feature – seen in ~94% cases)
  • Tinnitus
  • Vestibular symptoms (e.g. vertigo, imbalance)

Larger tumours can compress nearby structures:

  • CN V (trigeminal nerve) palsy → facial numbness, reduced corneal reflex
  • CN VII (facial nerve) palsy → facial weakness, inability to close the eyelids completely (can cause exposure keratopathy)
  • Possible life-threatening complications like brainstem compression and hydrocephalus (in extremely large tumours)

In most cases, clinical features of vestibular schwannoma present unilaterally.

Bilateral vestibular schwannoma is a hallmark clinical sign of neurofibromatosis type 2.

Investigation and Diagnosis

Neuroimaging (diagnostic) Gold standard and 1st line: MRI of the internal auditory meatus with contrast

  • Classic finding: well-defined enhancing mass arising in the internal acoustic meatus +/- extension into the cerebellopontine angle

CT is used for pre-operative planning and to assess bony surgical anatomy of the skull base

Hearing test Objective audiometric assessment (pure tone audiogram and speech discrimination)

Hearing function influences treatment decisions (e.g. whether to attempt to preserve hearing or not)

Biopsy Biopsy and histological diagnosis is NOT always required to make a diagnosis, especially if MRI findings are definitive

However, histological analysis is still performed post-surgical resection to assess morphology and immunohistochemistry

NF2 Screening Consider genetic screening for neurofibromatosis type 2 if a patient <30 y/o presents with a unilateral vestibular schwannoma

Management

Key management options are:

  • Active observation (annual MRI follow-up for 5 years)
  • Stereotactic radiosurgery
  • Surgery

Decision algorithm (simplified, unlikely to be examined in detail):

Scenario Recommended management
Small, asymptomatic tumour
  • Management of choice: active observation
  • Alternative: stereotactic radiosurgery – if it is intended to proactively stop tumour growth and preserve long-term nerve function before any symptoms or deterioration begins
Small, symptomatic tumour
  • If with impaired hearing → stereotactic radiosurgery
  • If there is complete hearing loss → stereotactic radiosurgery or active observation
Medium-sized tumours
  • Stereotactic radiosurgery, or
  • Surgery
Large tumour with brainstem compression
  • Surgical decompression is mandatory (often followed by stereotactic radiosurgery or observation)
Neurofibromatosis type 2
  • Bevacizumab can improve hearing and reduce tumour volume
  • Surgery is used for brainstem compression
  • Stereotactic radiosurgery for residual tumours
  • Shorter observation intervals are necessary (6-12 months)

Hearing aids should be offered as a standard supportive care measure to those with reduced hearing (see the Hearing Loss article for more information).

References

Related Articles

Hearing Loss

Vertigo

Vestibular Neuronitis and Labyrinthitis

Brain Tumours in Adults

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.